New research reveals that subtle response-time biomarkers—captured in minutes via digital assessments—can flag Alzheimer's and dementia risk far earlier than...
North Bergen, New Jersey--(Newsfile Corp. - June 26, 2025) - Apollo Biowellness, Inc. formerly known as Resonate Blends, Inc. (OTC...
Hybrid, decentralized trial of bezisterim in early Parkinson’s Disease prioritizes patient access and participationCARSON CITY, Nev., June 26, 2025 (GLOBE...
U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated...
Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in...
TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
DAYTON, Ohio and CINCINNATI, June 25, 2025 /PRNewswire/ -- Independent creative strategy, branding, and experience design agency Hyperquake today announced...
Neuro-inspired Computation and Entrepreneurship Workshop Will Equip the Next Generation of Neuroscience Entrepreneurs with Foundational Tools for Startup Creation TOKYO,...
June 25, 2025 Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis...
Non-dilutive funding extends Ovid’s operational runway; Immedica assumes certain ganaxolone IP costsNEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE...
To discuss the unmet medical need in Borderline Personality Disorder (BPD) and the design of vafidemstat’s Phase III PORTICO-2 trial...
Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Includes Positive...
The Award Highlights the Promise of Exclusively Targeting Peripheral Opioid Receptors to Treat Chronic Pain Without the Risk of Addiction...
Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in...
- End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer’s Disease Scheduled - - Applications for IND and Breakthrough Status Filed...
Phase 1/2a clinical trial currently supported by a $3.0 million grant from the U.S. Department of Defense Trial will enroll...
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"),...
LONDON, June 25, 2025 /PRNewswire/ -- The Longitude Prize on ALS, a £7.5 million global challenge prize, has launched to...
Innovate GBM Community Innovate GBM’s Community Members gather at the NASDAQ Closing Bell Ceremony—united in a mission to bridge the...
TORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a company...